Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer

Completed · Phase 2

Conditions studied: Ovarian Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with recurrent or unresectable epithelial ovarian cancer that has been previously treated with platinum-based chemotherapy.

Key facts

Study ID

NCT00002671

Run by

NYU Langone Health

Starts

1995-12-01

Last updated by the study team

2012-11-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Riverview Medical Center — Red Bank, New Jersey, United States
• Overlook Hospital — Summit, New Jersey, United States
• NYU School of Medicine's Kaplan Comprehensive Cancer Center — New York, New York, United States
• New York Presbyterian Hospital - Cornell Campus — New York, New York, United States
• Mount Sinai Medical Center, NY — New York, New York, United States
• Albert Einstein Comprehensive Cancer Center — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.